First of all, I would like to thank all the editorial board members, distinguished foreign and domestic authors, and reviewers for their efforts in getting the non-alcoholic fatty liver disease (NAFLD) review series published. This NAFLD review series is on a continuum with “KASL Clinical Practice Guideline: Management of Nonalcoholic Fatty Liver Disease” published in Clinical and Molecular Hepatology in 2021. The contents that could not be described in detail due to the limited space in this KASL guideline were divided into more detailed categorization, so that we can further provide useful information to our readers. This NAFLD review is composed of 26 topics, covering everything about NAFLD from its epidemiology to treatment. Recently, many researchers have been working to find drugs that help treat NAFLD, and I believe that the now is the best time to publish this NAFLD review series, as we are expecting new effective drugs to be released soon.

I would also like to thank Professor Si Hyun Bae, the President of the Korean Association for the Study of the Liver, as well as Professor Yoon Jun Kim, the President of the Korean NAFLD Study Group, for their support for the completion of the NAFLD review series. Thank you very much.

Citations to this article as recorded by